Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV-Olig001-ASPA gene therapy in Canavan Disease
NCT04833907Phase 2Enrolling by invitation
- Sponsor
- Myrtelle
- Start
- Apr 2021
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of MYR-101 in Canavan disease, sponsored by Myrtelle. Started Apr 2021; status: enrolling by invitation.
02
Drugs
MYR-101
03
Conditions
Canavan disease
Beyond the preview
Go deeper on NCT04833907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833907.